Galena Biopharma Inc (GALE): Improving Cancer Vaccines for the Future

Page 1 of 2

There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma Inc (NASDAQ:GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax.

The company’s market cap is at $205.4 million and for a company that has its Neuvax Vaccine currently in a phase 3 trial I think it is still pretty cheap. The stock price is currently around $2.81 per share, and like many small cap biotech stocks it is still very risky. Although I believe that Galena has a huge vaccine on its hands, and if it plays out the stock will pop up big.

Market Opportunity

The breast cancer market will be a huge opportunity if Galena Biopharma Inc (NASDAQ:GALE) can perfect its vaccine. The breast cancer market is expected to reach $10.2 billion dollars worldwide by the year 2019. There is a drawback however, GALE only targets the patients who are classified as HER2-Negative. Meaning patients who can achieve remission on standard of care, but have no vaccine therapy to keep them disease free afterwards.

Still if Galena Biopharma Inc (NASDAQ:GALE) is successful the company will be valued in the billions. There are about 232,340 breast cancer cases each year, and from that around 39,620 people die from it each year.  So for a vaccine company like Gale to be able to treat the other portion of the population that can’t be treated with Herceptin, would be huge opportunity. Another alarming statistic going forward is that 1 in 8 U.S. women, or 12% will develop breast cancer over their lifetimes.

Results that Count

In the Neuvax phase 2 trial, 187 patients were enrolled in the vaccine study. The 108 patients in the trial received the Neuvax vaccine from Galena Biopharma Inc (NASDAQ:GALE), and the control group received standard of care only.  Upon a 60 month median follow up, it was shown that the patients who took Neuvax experienced a 10.6% recurrence rate. This compares better to the control group only having a recurrence rate of 20.3%.

The fact is that Neuvax has shown promising results in that phase 2 study follow up, and is now currently in its phase three trial. The company has also recently acquired an FDA approved drug named “Abstral” from Orexo AB pharma in Sweden. Abstral is used for patients that have severe pain with cancer. The good part about Galena Biopharma Inc (NASDAQ:GALE) acquiring this drug is that it will minimize its risk of having to dilute the stock in the future for cash. Which is why I maintain that the stock value should be higher than its current price. The company now has enough cash to run its trials until 2014, so it may be awhile until it burns through its current cash.

Vical Incorporated (NASDAQ:VICL)‘s Allovectin

It seems that there are many other competitors in the cancer vaccine space. Vical Incorporated (NASDAQ:VICL) is another small cap biotech stock looking to conquer cancer with its vaccine pipeline. Vical Incorporated (NASDAQ:VICL) is currently in phase 3 testing for a skin cancer known as Melanoma. Allovectin has been indicated to treat stage 3, and stage 4 Melanoma. The company is looking for Allovectin to be first-line treatment for melanoma patients. The company thinks that Allovectin can become more efficacious than all other current first line treatments for this indication.

The company trades at a Market cap of $317.6 million, and the results may come out by late 2013. Vical trades currently at $3.46 per share, which is off of its 52 week high of $4.74. I still consider this stock as a risk like all other small cap biotech stocks, but like Galena Biopharma Inc (NASDAQ:GALE) this is also in a phase 3 study. If all goes well the company will make a lot of profit for investors. The reason being, is that the Melanoma cancer market will reach $1.15 billion by 2015.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!